Business Context and Reporting Period
This Form 8-K is a current report filed by American BriVision (Holding) Corporation (also referenced as ABVC Biopharma, Inc.) on March 30, 2020. The filing addresses the impact of the COVID-19 pandemic on the Company's operations and its ability to meet regulatory filing deadlines.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on operational disruptions and regulatory compliance rather than financial performance data.
Material Changes and Operational Impact
- 10-K Filing Extension: The Company is utilizing an SEC order issued on March 4, 2020, to extend the filing deadline for its Annual Report on Form 10-K for the period ended December 31, 2019. The new expected filing date is May 14, 2020.
- Operational Disruptions: Headquarters in the San Francisco Bay Area and subsidiary BioKey, Inc. are subject to "shelter-in-place" orders. Subsidiary BioLite, Inc. in Taiwan faces extended auditing times due to travel bans and quarantine mandates.
- Project Delays: The Company cannot conduct on-site inspections or quality control for raw materials in Mainland China for projects ABV-1504, ABV-1505, and ABV-1601. Due diligence for projects ABV-1505 and ABV-1701 with partners in the US, China, and Japan is suspended.
- Staffing: Non-essential travel is suspended, and some US employees have taken leave of absence, though no employees have exhibited COVID-19 symptoms.
Guidance, Risks, and Management Commentary
Management has supplemented risk factors to include the potential adverse effects of unfavorable global economic conditions and health safety concerns. The Company notes that scientific activities, including medical research and clinical trials, may be postponed for an extended period. Forward-looking statements regarding the duration of the outbreak, recovery pace, and impact on demand are subject to significant uncertainty. The Company does not undertake an obligation to update these statements except as required by law.
Investor Verification Checklist
- Verify the actual filing date of the delayed Form 10-K for the year ended December 31, 2019.
- Monitor the status of clinical trials and due diligence for projects ABV-1504, ABV-1505, ABV-1601, and ABV-1701.
- Assess the impact of the "shelter-in-place" orders on the Company's cash burn rate and operational costs.
- Review subsequent filings for updates on the resumption of on-site inspections in Mainland China.